JPMorgan analyst Chris Schott sees a favorable setup and risk/reward for Mylan shares heading into June. His downside case, in which biosimilar Neulasta, generic Advair and generic Restasis do not get approved in 2018, supports earnings per share in the low $5 range and a stock that he struggles to see sustainably below the mid $30's. The analyst's upside case, which has some mix of Advair, Neulasta and Restasis approved, supports a share price "well above" $50. Looking beyond near-term catalysts, Schott believes Mylan is "very well-positioned" within the generics space. He keeps an Overweight rating on the shares with a $53 price target.